The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 801–900 of 1,003
Jackson, A. B., Bağdaş, D., Muldoon, P. P., Lichtman, A. H., Carroll, F. I., Greenwald, M. K., Miles, M. F., & Damaj, M. I. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.005 · Cited by 33
“Nicotine withdrawal signs attenuated by PPARa agonist WY14643 The physical (somatic signs and hyperalgesia) and affective (anxiety-related behavior) signs of nicotine withdrawal were measured in mice following pretreatment with eitherWY-14643 or vehicle 15 min prior to mecamylamine administration on day 15.”
InfluentialChoi, J., Ko, Y., Lee, H. S., Park, Y. S., Yang, Y. D., & Yoon, S. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.09.042 · Cited by 33
Enhanced VDUP‐1 gene expression by PPARγ agonist induces apoptosis in human macrophage
Billiet, L., Furman, C., Larigauderie, G., Copin, C., Page, S., Fruchart, J., Brand, K., & Rouis, M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21179 · Cited by 38
Johnston, T. P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01138.x · Cited by 38
“These authors reported evidence for specific mechanisms through which lipoprotein metabolism can regulate distinct transcriptional responses through peroxisome proliferator-activated receptors (PPARs),([11,12]) ligand-activated nuclear receptors involved in the transcriptional regulation of metabolism, inflammation an…”
BackgroundStandeven, A. M., Thacher, S. M., Yuan, Y.-D., Escobar, M., Vuligonda, V., Beard, R. L., & Chandraratna, R. A. S. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00803-6 · Cited by 33
Mogensen, J. P., Jeppesen, L., Bury, P. S., Pettersson, I., Fleckner, J., Nehlin, J. O., Frederiksen, K. S., Albrektsen, T., Din, N., Mortensen, S. B., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00881-8 · Cited by 33
Kim, H. J., Hwang, J., Kim, H. J., Choi, W. S., Lee, J. H., Kim, H. J., Chang, K. C., Nishinaka, T., Yabe‐Nishimura, C., & Seo, H. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2062 · Cited by 38
Honda, A., Kamata, S., Akahane, M., Machida, Y., Uchii, K., Shiiyama, Y., Habu, Y., Miyawaki, S., Kaneko, C., Oyama, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094726 · Cited by 32
“Classical fibrates, such as bezafibrate and fenofibrate, are known to have relatively low PPAR activity and selectivity [28].”
BackgroundPPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 35
Medina‐Franco, J. L., Méndez‐Lucio, O., & Martínez‐Mayorga, K. (2014) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2014.06.001 · Cited by 32
Yao, L., Wen, J., Liu, S., Tan, R., Wood, N. M., Chen, W., Zhang, S., & Zhang, X. (2015) · Chemical Communications · doi:10.1039/c5cc09089j · Cited by 32
Zheng, Z., Yang, Y., Lu, X., Zhang, H., Shui, X., Liu, C., He, X., Jiang, Q. L., Zhao, B., & Si, S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.068 · Cited by 32
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists
Luckhurst, C. A., Stein, L., Furber, M., Webb, N. A., Ratcliffe, M., Allenby, G., Botterell, S., Tomlinson, W., Martin, B. P., & Walding, A. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.117 · Cited by 32
Giaginis, C., Politi, E. N., Alexandrou, P. T., Sfiniadakis, J., Kouraklis, G. P., & Theocharis, S. E. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9517-9 · Cited by 32
Rapid Racemization in Thiazolidinediones: A Quantum Chemical Study
Bharatam, P. V., & Khanna, S. (2004) · The Journal of Physical Chemistry A · doi:10.1021/jp0366522 · Cited by 32
Motawi, T. M. K., Hashem, R. M., Rashed, L. A., & El-Razek, S. M. A. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.10.0010 · Cited by 30
Peroxisome Proliferator-Activated Receptors and Atherosclerosis
Šoškić, S., Dobutović, B., Sudar-Milovanovic, E. M., Obradovic, M. M., Nikolić, D., Zarić, B. L., Stojanović, S. Đ., Stokić, E., Mikhailidis, D. P., & Isenović, E. R. (2011) · Angiology · doi:10.1177/0003319711401012 · Cited by 33
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics
Ce, L., Bilker, W., Brensinger, C. M., Han, X., Flory, J., Flockhart, D. A., Gagne, J., Cardillo, S., & Hennessy, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.297 · Cited by 36
“(27) Further, some fibrates also act at PPAR γ,(28) the site of action of TZDs.”
Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment
Uemura, H., Ishiguro, H., & Kubota, Y. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01937.x · Cited by 33
Hussein, M. A. (2011) · Free Radicals and Antioxidants · doi:10.5530/ax.2011.1.9 · Cited by 33
Ciuceis, C. D., Amiri, F., Iglarz, M., Cohn, J. S., Touyz, R. M., & Schiffrin, E. L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707215 · Cited by 32
“PPARg is implicated in adipocyte differentiation, cellular energy homeostasis and regulation of genes that affect insulin activity (Willson et al., 2000; Schiffrin et al., 2003) whereas PPARb/d is expressed ubiquitously and is involved in fatty acid oxidation (Gilde et al., 2003).”
BackgroundA novel PPARα agonist ameliorates insulin resistance in dogs fed a high-fat diet
Tsunoda, M., Kobayashi, N., Ide, T., Utsumi, M., Nagasawa, M., & Murakami, K. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00627.2007 · Cited by 34
Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials
Robins, S. J., & Bloomfield, H. E. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mol.0000236370.27508.9d · Cited by 36
Lee, B. C., Dence, C. S., Zhou, H., Parent, E. E., Welch, M. J., & Katzenellenbogen, J. A. (2009) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2008.11.002 · Cited by 31
Zhou, J., Ren, T., Li, Y., Cheng, A., Xie, W., Xu, L., Lu, P., Lin, J., Lian, L., Diao, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18097 · Cited by 34
“PPARα is a ligand-activated transcription factor that is involved in various skin diseases, such as psoriasis, acne, atopic dermatitis, scleroderma and melanoma [26].”
BackgroundZhuo, X., Wu, Y. R., Yang, Y., Gao, L., Qiao, X., & Chen, T. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116745 · Cited by 33
Ogawa, K., Yagi, T., Guo, T., Takeda, K., Ohguchi, H., Koyama, H., Aotani, D., Imaeda, K., Kataoka, H., & Tanaka, T. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.118 · Cited by 31
PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy
Huang, R., Zhang, C., Wang, X., & Hu, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.600618 · Cited by 37
Ouchi, Y., Watanabe, M., Ida, Y., Ohguro, H., & Hikage, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147335 · Cited by 31
“Thus, PPARγ agonists have received great attention for their efficacy in regulating adipocyte differentiation as well as increasing insulin sensitivity in diabetic patients [20,23,24].”
BackgroundFenofibrate in primary sclerosing cholangitis; a randomized, double‐blind, placebo‐controlled trial
Hatami, B., Mosala, M., Hassani, A. H., Ardakani, M. J. E., Gholami, S., & Zali, M. R. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.984 · Cited by 31
Giaginis, C., Spanopoulou, E., & Theocharis, S. E. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.8.1049 · Cited by 35
“PPARs are nuclear hormone receptors, initially described as molecular targets for compounds that induce peroxisomal proliferation [8,9] .”
BackgroundInfluentialCalleri, E., Fracchiolla, G., Montanari, R., Pochetti, G., Lavecchia, A., Loiodice, F., Laghezza, A., Piemontese, L., Massolini, G., & Temporini, C. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.10.037 · Cited by 33
Tributyltin is a potent inhibitor of piscine peroxisome proliferator-activated receptor α and β
Colliar, L., Sturm, A., & Leaver, M. J. (2010) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2010.10.008 · Cited by 43
Adida, A., & Spener, F. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2002.0404 · Cited by 35
Jossic-Corcos, C. L., Duclos, S., Ramirez, L. C., Zaghini, I., Chevillard, G., Martin, P. G. P., Pineau, T., & Bournot, P. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2004.04.004 · Cited by 31
New treatments/targets for primary biliary cholangitis
Corpechot, C., Poupon, R. Y., & Chazouillères, O. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.05.005 · Cited by 32
“Some fibrates, such as bezafibrate, further exhibit additional affinities for PPAR-δ and PPAR-γ, the other 2 isoforms of PPARs involved in energymetabolism and inflammatory processes.(44) Fibrates are also known to repress bile acid synthesis in the liver and to increase phospholipid excretion into the bile.”
BackgroundFracchiolla, G., Laghezza, A., Piemontese, L., Carbonara, G., Lavecchia, A., Tortorella, P., Crestani, M., Novellino, E., & Loiodice, F. (2007) · ChemMedChem · doi:10.1002/cmdc.200600307 · Cited by 33
García-Bates, T. M., Lehmann, G. M., Simpson‐Haidaris, P. J., Bernstein, S. H., Sime, P. J., & Phipps, R. P. (2008) · PPAR Research · doi:10.1155/2008/834612 · Cited by 34
“These include lysophosphatidic acid [50], nitrolinoleic acid [51], 9- and 13-hydroxyoctadecadienoic acids (9- and 13-HODE) [48, 52], 15-hydroxyeicosatetraenoic acid (15HETE) [25], prostaglandin D2 (PGD2), and 15-deoxy-Δ12,14prostaglandin J2 (15d-PGJ2) [25, 48, 49, 53–55].”
BackgroundInfluentialLöffler, M. G., Bilban, M., Reimers, M., Waldhäusl, W. K., & Stulnig, T. M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093831 · Cited by 37
“Transcriptional regulation by agonists of peroxisome proliferator-activated receptor (PPAR) , PPAR , and LXR comprise genes involved in gluconeogenesis, fatty acid metabolism, and ketogenesis (Venkateswaran et al., 2000; Willson et al., 2000).”
BackgroundOates, J. C., Reilly, C. M., Crosby, M. B., & Gilkeson, G. S. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10052 · Cited by 34
Coort, S. L., Coumans, W. A., Bonen, A., Vusse, G. J., Glatz, J. F. C., & Luiken, J. J. F. P. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400426-jlr200 · Cited by 31
Plutzky, J. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.017 · Cited by 31
“Peroxisome proliferator-activated receptors (PPARs) were one such group of orphan receptors, with three different isoforms: PPAR-alpha (- ), PPAR-gamma (- ), and PPAR-delta (- ) (2).”
InfluentialLi, H., Yang, Y., Gao, T., Li, R., Wang, C., Wang, X., Zhao, T., Tian, Q., Zhang, Z.-X., Zhang, R., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.02.016 · Cited by 37
“PPAR γ activates natural and synthetic ligands such as 15d-PGJ2 [61], antidiabetic thiazolidinediones (TZDs), and GW1929 compounds [62].”
Hoshino, K., Ishiguro, H., Teranishi, J., Yoshida, S., Umemura, S., Kubota, Y., & Uemura, H. (2010) · The Prostate · doi:10.1002/pros.21312 · Cited by 33
Hasan, M. S., Feugang, J. M., & Liao, S. F. (2019) · Current Developments in Nutrition · doi:10.1093/cdn/nzz082 · Cited by 33
“Biomedical studies have shown that dietary fat, a vital class of nutrients and a source of energy, can regulate gene expression through well-characterized transcription factors such as peroxisome proliferator-activated receptors (PPARs), hepatocyte nuclear factor 4α (HNF4A), NF-κB, and sterol regulatory element bindin…”
BackgroundThe multi-faceted role of retinoid X receptor in cardiovascular diseases
Shao, M., Lu, L., Wang, Q. Q., Ma, L., Tian, X., Li, C., Li, C., Guo, D., Wang, Q., Wang, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111264 · Cited by 31
Houri, I., & Hirschfield, G. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.06.006 · Cited by 33
Linking αMSH with PPARγ in B16‐F10 melanoma
Maresca, V., Flori, E., Camera, E., Bellei, B., Aspite, N., Ludovici, M., Catricalà, C., Cardinali, G., & Picardo, M. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01042.x · Cited by 32
“PPARs belong to the nuclear hormone recep- tor super-family and regulate the expression of target genes containing PPAR-responsive elements in their promoter (Palmer et al., 1995; Willson et al., 2000).”
BackgroundMethodResultInfluentialEmery, S. M., Alotaibi, M. R., Tao, Q., Selley, D. E., Lichtman, A. H., & Gewirtz, D. A. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.205120 · Cited by 33
“7, D and E) reduced the antiproliferative effects of WIN2 (Doherty et al., 2005; Willson et al., 2000).”
BackgroundRau, O., Syha, Y., Zettl, H., Kock, M., Bock, A., & Schubert‐Zsilavecz, M. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200700209 · Cited by 30
Mendieta‐Moctezuma, A., Jiménez, F., Garduño‐Siciliano, L., Mojica-Villegas, A., Rosales-Acosta, B., Villa‐Tanaca, L., Chamorro, G., Medina‐Franco, J. L., Meurice, N., Gutiérrez, R. U., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.09.022 · Cited by 31
Mammalian Ste20-Like Kinase and SAV1 Promote 3T3-L1 Adipocyte Differentiation by Activation of PPARγ
Park, B. H., Kim, D. S., Won, G. W., Jeon, H. J., Oh, B., Lee, Y., Kim, E., & Lee, Y. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030983 · Cited by 34
“Peroxisome proliferator-activated receptor c (PPARc) is a member of the ligand-dependent nuclear hormone receptor family [18] and is a transcription factor that is activated by the insulinsensitizing drugs, thiazolidinediones [19].”
BackgroundActivation of testicular orphan receptor 4 by fatty acids
Tsai, N., Huq, M. D. M., Gupta, P. K., Yamamoto, K., Kagechika, H., & Wei, L. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.09.010 · Cited by 30
“Such receptor-activating compounds could potentially be used as drugs in therapeutic applications [2,3].”
BackgroundEffect of green tea polyphenols on the genes with atherosclerotic potential
Kaul, D., Sikand, K., & Shukla, A. R. (2004) · Phytotherapy Research · doi:10.1002/ptr.1411 · Cited by 30
“…were recognized to play a crucial role in the interplay of these processes responsible for atherogenesis (Brown and Goldstein, 1986; Repa et al., 2000; Wilson et al., 2000; Bishop-Bailey, 2000; Stacks et al., 1998; Galetto et al., 2001; Nicholson et al., 2001; Bocher et al., 2002; de Nigris et…”
In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist
Stebbins, K. J., Broadhead, A. R., Cabrera, G., Correa, L. D., Messmer, D., Bundey, R. A., Baccei, C. S., Bravo, Y., Chen, A. C., Stock, N. S., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.008 · Cited by 30
Pioglitazone Improves Mitochondrial Organization and Bioenergetics in Down Syndrome Cells
Mollo, N., Nitti, M. P., Zerillo, L., Faicchia, D., Micillo, T., Accarino, R., Secondo, A., Petrozziello, T., Calì, G., Cicatiello, R., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00606 · Cited by 31
Estrogen‐Associated Genes in Uterine Leiomyoma
Li, S., & McLachlan, J. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03992.x · Cited by 30
Azukizawa, S., Kasai, M., Takahashi, K., Miike, T., Kunishiro, K., Kanda, M., Mukai, C., & Shirahase, H. (2008) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.56.335 · Cited by 30
Vedani, A., Descloux, A.-V., Spreafico, M., & Ernst, B. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2007.06.011 · Cited by 31
Seo, M., Inoue, I., Ikeda, M., Nakano, T., Takahashi, S., Katayama, S., & Komoda, T. (2008) · PPAR Research · doi:10.1155/2008/316306 · Cited by 30
“The peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor superfamily and play an important role in the regulation of lipid and glucose metabolism and adipocyte differentiation [12, 13].”
BackgroundRodrigues, G. A., Maurier, F., Shurland, D., McLaughlin, A. P., Luhrs, K. A., Throo, E., Delalonde-Delaunay, L., Pallares, D., Schweighoffer, F., & Donello, J. E. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-5715 · Cited by 33
Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists
Grether, U., Benardeau, A. M., Benz, J., Binggeli, A., Blum, D., Hilpert, H., Kuhn, B., Märki, H. P., Meyer, M., Mohr, P., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800425 · Cited by 36
Casimiro‐Garcia, A., Bigge, C. F., Davis, J. A., Padalino, T., Pulaski, J., Ohren, J. F., McConnell, P., Kane, C. D., Royer, L. J., Stevens, K. A., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.03.043 · Cited by 34
Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor γ in Human Macrophages
Rigamonti, E., Fontaine, C., Lefebvre, B., Duhem, C., Lefèbvre, P., Marx, N., Staels, B., & Chinetti, G. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.161679 · Cited by 32
Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes
Ahmed, I., Furlong, K., Flood, J. J., Treat, V., & Goldstein, B. J. (2007) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000212890.82339.8d · Cited by 33
“This process activates the transcription of the regulated gene.18 The second mechanism, transrepression, involves interfering with other transcription factor pathways in a DNA-independent fashion and may explain the antiinflammatory actions of PPARs.22 Tissue distribution, ligands, and target genes of PPARs The tissue…”
BackgroundInfluential2D QSAR of PPARγ agonist binding and transactivation
Rücker, C., Scarsi, M., & Meringer, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.04.005 · Cited by 30
Suchanek, K. M., May, F. J., Lee, W. J., Holman, N. A., & Roberts‐Thomson, S. J. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00025-0 · Cited by 30
Fernández, A. Z. (2008) · PPAR Research · doi:10.1155/2008/285842 · Cited by 30
“The regulation of the inflammatory pathways by PPARs can be achieved on each one of the cells involved in the atherosclerotic process, that is, monocytes, macrophages, T cells, endothelial cells, and smooth muscle cells.”
InfluentialNicchio, I. G., Cirelli, T., Quil, L. C. D. C., Camilli, Â. C., Scarel‐Caminaga, R. M., & Leite, F. R. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116908 · Cited by 29
Zhang, Y., Lickteig, A. J., Csanaky, I. L., & Klaassen, C. D. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx191 · Cited by 29
Efficient synthesis of arylsulfamides by reaction of amines with arylsulfamoyl imidazolium triflate
Lee, H. K., Bang, M., & Pak, C. S. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.08.092 · Cited by 29
Barón-Mendoza, I., & González-Arenas, A. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1755793 · Cited by 33
“the subsequent binding of co-activators and co-repressors, gene expression is repressed or promoted [37].”
BackgroundNeobavaisoflavone Induces Bilirubin Metabolizing Enzyme UGT1A1 via PPARα and PPARγ
Zhu, Y.-D., Guan, X., Chen, J., Peng, S., Finel, M., Zhao, Y.-Y., Wang, R., Bi, H., Lei, M., Wang, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.628314 · Cited by 29
“PPARα has been validated as a key regulator or controller of lipid metabolism (Brown and Plutzky, 2007; Willson et al., 2000).”
BackgroundMethodSameeh, M. Y., Khowdiary, M. M., Nassar, H. S., Abdelall, M. M., Amer, H. H., Hamed, A., & Elhenawy, A. A. (2022) · Molecules · doi:10.3390/molecules27030830 · Cited by 31
“The chemical reactivity for 4–7 was computed in (Table 1), like; η, hardness (quantifies the resistance to change in the electron distribution in a collection of nuclei and electrons); S, softness (reciprocal of hardness) [39]; μ, chemical potential; χ, electronegativity strength [40]; the μ−, electron donating power;…”
BackgroundDesign and synthesis of marine fungal phthalide derivatives as PPAR-γ agonists
Xiao, B., Yin, J., Park, M., Liu, J., Li, J. L., Kim, E. L., Hong, J., Chung, H. Y., & Jung, J. H. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.06.039 · Cited by 29
Stimulation of Resorption in Cultured Mouse Calvarial Bones by Thiazolidinediones
Schwab, A., Granholm, S., Persson, E., Wilkes, B., Lerner, U. H., & Conaway, H. H. (2005) · Endocrinology · doi:10.1210/en.2005-0601 · Cited by 30
Rosa, A. O., Egea, J., Martínez, A., García, A. G., & López, M. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.03.008 · Cited by 31
Schäfer, S., HANSEN, B. C., Völkl, A., Fahimi, H. D., & Pill, J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.004 · Cited by 30
3,4,5-Trisubstituted isoxazoles as novel PPARδ agonists. Part 2
Epple, R., Azimioara, M. D., Russo, R., Xie, Y., Wang, X., Cow, C., Wityak, J., Karanewsky, D. S., Bursulaya, B. D., Kreusch, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.052 · Cited by 29
Kawasaki, M., Kambe, A., Yamamoto, Y., Arulmozhiraja, S., Ito, S., Nakagawa, Y., Tokiwa, H., Nakano, S., & Shimano, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010361 · Cited by 31
“Several PPARα and PPARγ agonists have been developed for now [1].”
BackgroundInfluentialKadayat, T. M., Shrestha, A., Jeon, Y. H., An, H., Kim, J., Cho, S. J., & Chin, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01882 · Cited by 29
Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis
Giaginis, C., Margeli, A. P., & Theocharis, S. E. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.10.1561 · Cited by 29
“The long chain polyunsaturated fatty acids and their derivatives, in particular prostaglandins (such as 15-deoxy-∆ 12,14 -prostaglandin J 2 [15d-PGJ 2 ] and 15-hydroxy-eicosatetraenoic acid), as well as nitrolinoleic acids, can function as natural PPARγ ligands [17,18] .”
BackgroundHong, S. S., Lee, J. H., Jeong, W., Kim, N., Jin, H. Z., Hwang, B. Y., Lee, H.-J., Lee, S., Jang, D. S., & Lee, D. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.070 · Cited by 29
PPARγAgonists: Potential as Therapeutics for Neovascular Retinopathies
Pershadsingh, H. A., & Moore, D. M. (2008) · PPAR Research · doi:10.1155/2008/164273 · Cited by 30
“Telmisartan and irbesartan appear to cause an alteration in the conformation of these helixes similar to that induced by nTZDpa [37, 39], promoting differences in receptor activation and target gene expression that confer a low adipogenic potential compared with full agonists (TZDfa) like rosiglitazone and pioglitazon…”
InfluentialGiaginis, C., Tsantili‐Kakoulidou, A., & Theocharis, S. E. (2008) · PPAR Research · doi:10.1155/2008/431763 · Cited by 34
“The long chain polyunsaturated fatty acids and their derivatives, such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), as well as nitrolinoleic acids are known natural occurring PPAR-γ ligands [14, 15].”
Kim, H. J., Woo, I. S., Kang, E. S., Eun, S. Y., Kim, H. J., Lee, J. H., Chang, K. C., Kim, J., & Seo, H. G. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.147 · Cited by 31
Alexandre, C. D. S., de Bragança, A. C., Shimizu, M. H. M., Sanches, T. R., Fortes, M. A. H. Z., Giorgi, R. R., Andrade, L., & Seguro, A. C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90256.2008 · Cited by 29
Weigand, S., Bischoff, H., Dittrich‐Wengenroth, E., Heckroth, H., Lang, D. H., Vaupel, A., & Woltering, M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.023 · Cited by 29
Martín, J. A., Brooks, D. A., Prieto, L., González, R., Torrado, A., Rojo, I., de Uralde, B. L., Lamas, C. J. E., Ferritto, R., Martín-Ortega, M. D., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.10.042 · Cited by 29
Xu, Y., Mirmalek-Sani, S.-H., Yang, X., Zhang, J., & Oreffo, R. O. C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.02.016 · Cited by 29
“Peroxisome proliferator activated receptor gamma [31,32], or PPARγ, is a nuclear receptor and regarded as a master regulator of adipogenesis and metabolic homeostasis [33].”
BackgroundInsulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions
Raji, A., & Plutzky, J. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0116-3 · Cited by 32
“Regardless, activated PPARs interact with defined response elements in the promoter regions (PPRE) of target genes, thus regulating their transcription [ 22 ].”
BackgroundInfluentialPeroxisome Proliferator-Activated Receptors
Heuvel, J. P. V., & Peters, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00209-8 · Cited by 30
Oxidative Stress and Peroxisome Proliferator–Activated Receptors: Reversing the Curse?
Devchand, P. R., Ziouzenkova, O., & Plutzky, J. (2004) · Circulation Research · doi:10.1161/01.res.0000151331.69399.b2 · Cited by 31
Berry (2007) · doi:10.1155/2007/73256 · Cited by 28
“Three PPAR subtypes, encoded for by three separate genes, are known to exist: PPARα, PPARβ/δ, and PPARγ [6].”
BackgroundDevelopment of Improved PPARβ/δ Inhibitors
Toth, P. M., Naruhn, S., Pape, V. F. S., Dörr, S., Klebe, G., Müller, R., & Diederich, W. E. (2011) · ChemMedChem · doi:10.1002/cmdc.201100408 · Cited by 31
Gopal, R., Mendy, A., Marinelli, M. A., Richwalls, L. J., Seger, P. J., Patel, S., McHugh, K. J., Rich, H. E. A., Grousd, J. A., Forno, E., et al. (2019) · Viruses · doi:10.3390/v11060505 · Cited by 28
Bezafibrate confers neuroprotection in the 5xFAD mouse model of Alzheimer's disease
Lu, Y., Fujioka, H., Wang, W., & Zhu, X. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166841 · Cited by 28
Laghezza, A., Montanari, R., Lavecchia, A., Piemontese, L., Pochetti, G., Iacobazzi, V., Infantino, V., Capelli, D., Bellis, M. D., Liantonio, A., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201402462 · Cited by 30
Lee, B. C., Lee, K. C., Lee, H. S., Mach, R. H., & Katzenellenbogen, J. A. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060191g · Cited by 28
Takahashi, H., Suzuki, H., Suda, K., Yamazaki, Y., TAKINO, A., Kim, Y., Goto, T., Iijima, Y., Aoki, K., Shibata, D., et al. (2013) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.130572 · Cited by 28
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.